Investor Signals

Cross-investor pattern matching — temperature, concerns, engagement.

Last updated: 2026-02-19 Calls analyzed: 10 completed + 4 scheduled Pipeline: 14 active investors (10 completed calls + 3 scheduled + 1 monitoring)

---

Active Pipeline

---

What Each Investor Cares About Most

Primary Ventures (Hannah McQuaid, Sam Tool)

• Cares about: Services + software model, founders who understand market, pull dynamics
• Worried about: Payer GTM speed (J2 Health PTSD), whether health plans actually buy
• Portfolio lens: Valerie Health (services model works), J2 Health (payer sales is brutal)
• Process: Low-volume (3-4 deals/pod/year), real diligence, fast IC (1-2 weeks)
• Investor type: Healthcare specialist — needs payer GTM conviction

Refract VC (Caesar Djavaherian, Kerry Kellogg)

• Cares about: Founder grit, scalability of tech vs. consulting, market size
• Worried about: Whether this is a consulting firm or a tech company, TAM
• Portfolio lens: Charter Health (Blue Cross Michigan, 7-figure — validates payer market), Cloud Gurus (offered intro)
• Process: Fast internal discussion ("couple of days"). Prior relationship from Wharton.
• Investor type: Healthcare-aware generalist — pre-sold on timing, needs scalability + TAM

NextGen VP (Deborah Chu)

• Cares about: Differentiation, long-term defensibility, clear end-state vision
• Worried about: "Underlying models are the same," consulting firm risk, unclear deep vs. broad strategy
• Portfolio lens: Fourier Health (AI medical record summarization, health systems, human in loop)
• Process: Cold outreach, no active process. "Potentially a fit" but not driving forward.
• Investor type: Digital health generalist — skeptical of AI differentiation broadly, needs strong thesis

Tau Ventures (Sam Bogrov)

• Cares about: Revenue before investing (Tau-specific policy), need a lead investor in place, domain expertise
• Worried about: Written positioning triggers "wrapper" fear — blurb doesn't match verbal pitch quality
• Portfolio lens: Alafia (fraud/miscoding for payers — adjacent payer AI)
• Process: Not investing this round. Valuable as positioning feedback and connector. Suggested intros: Zen/Emily, Tara (Flair), Hippo.
• Investor type: Healthcare seed specialist — gets the thesis, wrong timing for their fund
• Key contribution: Produced the best revenue model articulation (SaaS + implementation + maintenance). Also flagged the "wrapper" positioning problem — critical intel.
• Market intel shared: Cigna contact says payer tech is "absolute trash," everything manual, pilots die from integration complexity. AI doctor regulatory shift in Utah.
• Valuation framing: 15-20% dilution at seed, ~5x round size math

Sorensen Capital (Chris Hulme, Eric)

• Cares about: Low concentration/high conviction, opening doors for portfolio, operator mentality, healthcare reimbursement complexity
• Worried about: Nothing surfaced — most positive initial reaction of any investor
• Portfolio lens: AI platform for SNFs (skilled nursing facilities) — same dynamics (reimbursement optimization, clinical data, time pressure). Chris drew parallels unprompted.
• Process: Fast. Intro → team review Monday → feedback Mon/Tue. Eric is the senior partner relationship.
• Investor type: Healthcare-aware generalist — pre-sold by problem-space familiarity from SNF portfolio
• Firm profile: $2-6M checks, low concentration high conviction, no ownership target, prefer co-lead. Best at opening doors.
• Key quote: "Huge problem, messy, sounds like a good opportunity" — most enthusiastic framing across all 6 calls
• What worked: Chris immediately understood problem space from SNF portfolio. Drew parallels unprompted. Payer-first rationale was clear. Bootstrapping story impressed. Bay Area rapport with Michael.

Seae Ventures (Karlos Bledsoe, Erica — MD)

• Cares about: FDE / consulting-first deployment model, workflow automation in care transitions, concurrent review differentiation
• Worried about: Competition — specifically Cohere/Cahir creeping into concurrent review. Karlos: "I'm positive that question's going to come up" with full team. This is THE diligence gate.
• Portfolio lens: Did diligence on Otter (gold carding, passed — payer behavior change issues). Talked to Felicity (agentic tailwinds). Vendor: Manatt Healthcare (source of "no successful AI companies, just consulting companies" quote).
• Process: Karlos took intro → routing to pre-seed MD Erica for full team pitch + demo. Erica at Viv next week. Analyst may also be at Viv.
• Investor type: Healthcare specialist — pre-sold by FDE philosophy (Manatt quote guiding their diligence), needs competitive conviction
• Key quote: "Pipeline is honestly pretty impressive traction for this stage." Unprompted: "I think this is a good one to get in front of our full team."
• Traction benchmark shared: Pre-seed companies typically NOT contracting with payers yet. Being in contracting is ahead of comps. Trade-off: comps usually have low $100K revenue.
• Network: Karlos overlapped with Michael at Princeton. Knows Avi Jayaraman (Wharton fellowship with Seae). Connected to Sahil/Felicity, Will Bramlett/Otter.

Define Ventures (Chuka Esiobu)

• Cares about: FDE thesis (validated unprompted), platform positioning over point solutions
• Worried about: Infrastructure bespoke-ness across payers (scaling concern). Suggested lightweight qualification step before full FDE engagement.
• Portfolio lens: Cohere (DIRECT CONFLICT — concurrent review competitor). Lynn from Kleiner Perkins.
• Process: Found DaisyAI on an unidentified "market map." 21-minute surface-level call. Noncommittal close.
• Investor type: Healthcare specialist — $800M AUM, largest early-stage healthcare fund. Ideation to Series B, $1-20M checks.
• Risk: Cohere portfolio conflict. Call pattern consistent with competitive intel gathering: short, surface-level, asked about specific client and stack position, didn't disclose conflict.
• Strategy: Do not chase. Do not send sensitive materials. If they follow up with genuine interest, engage cautiously.

Wavemaker 360 Health (Michelle Wang)

• Cares about: Concrete ROI, workflow integration, customer validation. Services-friendly — "I'd rather have honest services revenue than fake ARR."
• Worried about: Timing — wants to see customer who can speak to the experience. Payer sales cycle slowness dragging out fundraising for all payer startups.
• Portfolio lens: Invoice AI (AI investment), various record interoperability companies. No direct payer UM comp.
• Process: Not driving a process. Wants updates. "We can check in after or whenever it makes sense."
• Investor type: Healthcare specialist — LP-network-driven fund, strategic capital model. Services-friendly, ROI-focused.
• Key contribution: Anterior Health intel ($40M raise, no real customers ~1yr ago). Validated that payer-focused seed startups are rare and early. Explicitly validated services > SaaS framing.
• Market intel shared: Anterior Health raised $40M but didn't have real customers/contracts as of ~1yr ago. Payer-facing startups "just haven't reached that clear path to velocity." Buy vs. build tension confirmed: payers want to build but lack resources.
• NYC-based: Flatiron office. Didn't realize DaisyAI was in NYC. In-person meetings possible.

Norwest Venture Partners (Bayan Alizadeh)

• Cares about: Product depth, seeing the actual product working, technical confidence
• Worried about: Demo didn't work (localhost auth failure) — explicitly said product demo is important for him
• Portfolio lens: Large fund, sweet spot is Series A but doing selective earlier deals ($1M pre-seed recently). Has dedicated healthcare team that makes the sector call.
• Process: Materials (deck + demo video) → Bayan first pass → socializes with healthcare team → decision on next conversation.
• Investor type: Cross-sector seed investor — product-focused (physics background), but healthcare team is the real gate
• Key contribution: EHR integration conversation showed strong technical depth (HL7, ADT/ORU). Bayan uses Claude for his own workflow (data room analysis). Technical rapport with Michael.
• Risk: Demo failure was a real miss for this investor specifically. Must recover with strong demo video.

---

Cross-Investor Patterns

Concerns That Cluster

| Concern | Battery | Primary | Refract | NextGen | Tau | Sorensen | Norwest | Seae | Define | Trend | |---------|---------|---------|---------|---------|-----|----------|---------|------|-------| | Scalability / consulting risk | — | — | Yes | Yes (main) | Yes | — | — | — | — | — | 3/10 — #1 question. NOW ANSWERED (Tau version). | | Contract / pricing specifics | Yes (weak) | Yes | Yes | — | — | — | Yes | — | — | Yes (parameters) | 5/10 — Tau framework resolves. | | Product demo | — | — | Yes (loved it) | — | — | — | Yes (missed) | Requested | — | — | 3/10 — strategic asset. Deploy by investor type. | | Competition / landscape | — | — | Yes (market size) | — | — | — | — | Yes (main) | — | Yes (mutual) | 3/10 — RECURRING. Seae + Wavemaker. Need one-pager. | | Payer GTM difficulty | — | Yes (main) | — | — | — | — | — | — | — | — | 1/10 — healthcare specialist concern | | Payer vs provider choice | Yes | — | Yes | — | — | Yes | — | — | — | — | 3/10 — strong answer every time | | Market size / TAM | — | — | Yes | — | — | — | — | — | — | — | 1/10 — growing | | Differentiation / moat | — | — | — | Yes (main) | — | — | — | — | — | — | 1/10 — generalist concern | | Vision / end state clarity | — | — | — | Yes | — | — | — | — | — | Yes (roadmap) | 2/10 — worth tightening | | Positioning / blurb quality | — | — | — | — | Yes | — | — | — | — | — | 1/10 — but affects pre-call impressions universally | | Data access / EHR integration | — | Yes | — | — | — | — | Yes | — | — | — | 2/10 — answered well both times | | Point solution / consolidation risk | Yes (implicit) | — | — | — | — | — | — | — | Yes (platform) | — | 2/10 — Define: "platform players" framing | | Infrastructure bespoke-ness / scaling | — | — | — | — | — | — | — | — | Yes | Yes (one vendor vs. many) | 2/10 — Define + Wavemaker flagged payer stack variability. | | Customer validation / proof points | — | — | — | — | — | — | — | — | — | Yes (main gate) | 1/10 — Wavemaker's explicit investment gate. |

Resonance Patterns

| Signal | Battery | Primary | Refract | NextGen | Tau | Sorensen | Norwest | Seae | Define | Trend | |--------|---------|---------|---------|---------|-----|----------|---------|------|-------| | Founder commitment / both build | Yes | Yes | Yes ("catnip") | Mild | Implicit | Yes (impressed) | Yes (engaged) | Implicit | Implicit | Implicit | Universal (10/10) | | Copilot / catalyst framing | — | Indirect | Yes (loved) | — | — | — | — | — | — | — | Strong when used | | Premera as proof point | Yes ("about to close") | Yes | Yes ("incredible") | Mentioned | — | — | — | Yes (pipeline) | Yes (engaged) | Yes (contracting) | Anchor for traction story (10/10) | | Payer pressure / why now | Yes (upcoding) | Yes | Yes | Yes | Yes (Cigna intel) | Yes (SNF parallels) | Yes | Yes (Blues LP) | Yes (appeals) | Yes (cost pressure) | Universal (10/10) | | Live product demo | — | — | Yes (crushed it) | — | — | — | Missed | Requested | — | — | Converts product-focused investors | | UM wedge rationale | — | — | — | Yes (strong) | — | — | — | Yes (concurrent) | — | Yes (appeals) | Good answer | | FDE/deployment model | Yes (validated) | Yes | Yes | Yes (accepted) | Yes | Yes | Yes | Yes (Manatt) | Yes (unprompted) | Yes (differentiated) | Universal — VCs comfortable (10/10) | | Revenue breakdown (Tau version) | — | — | — | — | Yes (breakthrough) | — | — | — | — | — | New standard — use every call | | Problem-space familiarity | Yes (Magnify) | — | Yes (Charter) | — | Yes (Alafia) | Yes (SNF AI) | — | Yes (BCBS roots) | Yes (Cohere) | Yes (payer AI) | Investors with adjacent portfolio = fastest converts | | EHR technical depth | — | — | — | — | — | — | Yes (strong) | — | — | — | Lands with technical investors | | Bootstrapping story | Yes | — | Yes | — | — | Yes | — | — | Yes | Yes | Strong signal for operator-type investors | | Payer-first rationale | Yes (strong) | — | Yes | — | — | Yes (strong) | — | — | Yes | Yes | Clear and accepted when tested (5/5) | | AI-on-AI dynamic (payer vs provider) | — | — | — | — | — | — | — | Yes (resonated) | Yes (appeals) | Yes (10x denials) | Emerging framing — provider AI creating payer pressure (3/3 when used) | | Services > SaaS thesis | — | — | — | — | — | — | — | — | — | Yes (explicit) | NEW — Michelle: "honest services revenue more sticky than fake ARR" |

Investor Segmentation (confirmed across 10 calls)

Key insight: Tailor the first 5 minutes to the investor type. Healthcare specialists need GTM conviction. Generalists need differentiation and scalability. Product-focused investors need demo early. Investors with adjacent portfolio companies (Sorensen: SNF AI, Refract: Charter Health, Tau: Alafia) skip the "is this real?" phase and go straight to business model. Target investors with payer/reimbursement portfolio exposure.

---

Signal Quality Guide

---

Temperature Changelog

---

Investor-Specific Prep Notes

For next Primary Ventures call (Sam Tool):

• Mon/Fri from Jersey — schedule accordingly
• Hannah will have briefed him — assume he knows basics
• Expect deeper GTM probe (partner will push harder)
• Have contract details tighter — use Tau framework
• Reference Valerie Health comp proactively
• Consider sending a product video beforehand or using the demo as the hook for this call

For next Refract interaction (Caesar/Kerry follow-up):

• Should have heard back by ~Feb 7-8
• Expect scalability and market size to lead
• Use Tau revenue breakdown (SaaS + implementation + maintenance)
• Prepare TAM framing with numbers
• Follow up on Cloud Gurus intro regardless
• Caesar is thinking with us, not just evaluating — use his advice

For Sorensen Capital (Monday/Tuesday feedback):

• Team review is Monday — expect feedback Mon PM/Tues AM
• This is the FASTEST and most enthusiastic process. Prioritize responsiveness.
• Chris already understood the problem space — don't re-explain, go deeper on execution plan, milestones, and team
• $2-6M checks, prefer co-lead, no ownership target. Ideal for our round structure.
• Eric is the partner — may need to meet him next
• Emphasize co-lead positioning — they prefer it, we want it
• Chris probed ideal partner profile — he's pattern-matching against his own firm. Lean into what makes Sorensen the right fit (opening doors, healthcare exposure).

For Norwest VP (materials follow-up):

• URGENT: Send deck + demo video. Bayan explicitly said product demo is important for him.
• Demo video must be strong — this is the recovery from the localhost failure
• EHR integration specifics (HL7/ADT/ORU) landed well — lean into technical depth in any follow-up
• Healthcare team members are the real gate — Bayan is the entry point
• If healthcare team wants a call, expect sector-specific questions (not product questions)
• Series A sweet spot but selectively earlier — frame as "early conviction" opportunity
• Connected on technical wavelength — future conversations should lead with product

For Tau Ventures (advisory relationship):

• Send deck — he offered to think about intros
• Follow up on suggested connections: Zen/Emily, Tara (Flair), Hippo
• Not investing this round but may revisit at next stage (post-revenue, post-lead)
• Continue using as positioning sounding board — his "wrapper" feedback was the most actionable intel from any call
• Use his feedback to fix the deck/blurb before sending to new investors

For NextGen (if re-engaging):

• Need substantially more clarity on vision + deep vs. broad before going back
• Frame as hypotheses (her advice): what we're testing, why, timeline
• Come with differentiation story — three layers of moat
• If possible, show demo — she didn't see product, only heard description
• Lower priority than Sorensen, Refract, Primary, and Norwest

For Seae Ventures full team pitch (Erica + team):

• Competition is THE diligence question — have competitive one-pager ready
• Karlos already sold on FDE model (Manatt quote alignment) — don't re-sell, go deeper
• Demo explicitly requested — have it polished and ready
• Traction story landed well — lean into pipeline specifics, Midwest payer engagement details
• Revenue model: use Tau framework (SaaS + implementation + maintenance)
• Erica is the decision-maker (MD, pre-seed side) — tailor for her
• Karlos won't be at Viv — meet Erica + analyst there, then schedule full team pitch separately
• Frame concurrent review as differentiated from crowded prior auth (Karlos already bought this)
• Cohere/Cahir answer: "They've been trying to get into concurrent for 2 years. To do this effectively you have to work with the payer — unless you're doing FDE, no one's interested in buying SaaS."

---

Competitive Intel (from investor conversations)

Market Intel from Investor Networks

• Battery: Ambient scribes caused upcoding → UM getting harder for payers (market tailwind). Procurement patterns "lumpy" post-scribe wave. FDE model emerging as adoption solution. Optera is the best FDE comp (6-12mo ahead, payers, risk/governance).
• Refract: JP Morgan healthcare event reinforced timing. Charter Health validates payer buying.
• Tau: Cigna contact says payer tech systems are "absolute trash," everything manual, pilots die from integration complexity. AI doctor regulatory shift in Utah.
• Sorensen: SNF portfolio company confirms reimbursement optimization + clinical data + time pressure is a massive, messy opportunity.
• Seae: Blues Plan LP confirmed payers "getting hammered" by provider AI tools + GLP-1s. Manatt Healthcare partner: "No successful AI companies in healthcare, just consulting companies." Karlos validated FDE model as exactly what their diligence favors. Otter (gold carding) failed due to payer behavior change issues. Concurrent review differentiated from "incredibly crowded" prior auth.
• Define: Validated FDE thesis unprompted ("a lot of talk within our ecosystem"). Cohere portfolio — confirms Cohere is still active in concurrent review space. Platform framing: "both providers and plans are going to want folks that touch a number of different use cases." Market map exists that includes DaisyAI.
• Wavemaker: Anterior Health raised $40M but no real customers as of ~1yr ago. Payer-facing startups haven't reached "clear path to velocity." Buy vs. build tension: payers want to build but lack resources. FDE bypasses the sales cycle by entering as employees rather than vendors — "basically impossible to go back from vendor to systems engineer."
• Pattern: Every investor with exposure to the problem space validates timing and opportunity. Market timing has never been challenged (0/10).

---

Market Perception

How the capital markets are seeing DaisyAI — distinct from individual investor interest. Tracking how we're being categorized, discovered, and understood.

Discovery Signals

How We're Being Categorized

Based on 9 investor interactions, the market appears to be placing DaisyAI in these mental models:

Market Dynamics Observed

• FDE as a category is solidifying. Multiple investors (Seae, Define, Battery) have independently referenced the "forward deployed" model as a thesis they're tracking. This isn't just our framing — the market is converging on it.
• Concurrent review is being mapped as a space. DaisyAI is appearing on market maps alongside Cohere, Otter, Latitude. We're being categorized as a concurrent review company whether we like it or not. The clearing house vision reframes this, but the market doesn't know that yet.
• Inbound is increasing. The shift from outbound (Battery, Primary, Refract, NextGen) to inbound (Define, Pear, Wavemaker, Sidekick) suggests growing market awareness.
• Cohere is the comp investors reach for. Define invests in them. Seae did diligence on adjacent players. Refract has Charter Health. The market is triangulating DaisyAI relative to existing funded companies in the payer AI space.
• The "SaaS apocalypse" thesis is landing. Multiple investors have validated that payers won't buy traditional SaaS. The FDE/services-first model is being accepted, not questioned. 10/10 calls have been comfortable with it. Wavemaker went further: Michelle explicitly prefers honest services revenue over "fake ARR."

What This Means Strategically

The capital markets are starting to see DaisyAI. The question is whether they see us as:

(a) Another concurrent review AI startup — in which case we're in a crowded category competing with better-funded players like Cohere.

(b) The FDE company for healthcare — a new category that happens to start with UM but is really about the deployment model and the clearing house position.

The vision doc (clearing house thesis) moves us toward (b), but the market currently sees (a). Every investor touchpoint is an opportunity to shift that perception. The competitive landscape one-pager (MCP-97) and the updated deck are critical for this repositioning.

---

Priority Actions (from signals analysis)

1. Monitor Sorensen Monday/Tuesday — fastest-moving process. Be ready for partner call.
2. Send materials to Norwest and Tau — Norwest needs deck + demo video. Tau needs deck for intro thinking.
3. Fix the blurb/deck — Tau's "wrapper" feedback means every investor reading materials pre-call may form wrong impression. Urgent.
4. Deploy demo URL or record video — never depend on localhost again. Product-focused investors (Bayan) need this.
5. Standardize revenue breakdown — Tau version (SaaS + implementation + maintenance) for every future call. Internalize.
6. Prepare TAM numbers — Refract flagged, others will too. Need bottom-up market sizing.
7. Follow up on intros — Refract (Cloud Gurus), Tau (Zen/Emily, Tara, Hippo).
8. Prep competitive landscape one-pager — Seae flagged competition as #1 diligence question. Need formal doc before full team pitch: prior auth companies ≠ competitors, Cohere/Cahir hasn't cracked concurrent, FDE is the moat, consulting orgs lack AI-native talent.
9. Connect with Erica (Seae MD) at Viv — She'll be there next week. Karlos making intro. In-person opportunity to advance the process.
10. Connect with Michelle Wang (Wavemaker) at ViVE — Both attending. NYC-based. In-person relationship building, not investment pitch. She wants customer validation first.